目前我国肺癌发病率呈迅速上升趋势,并已成为城市癌症死亡的主要原因。非小细胞肺癌(NSCLC)约占肺癌的80%,并且大多数患者就诊时已失去手术机会。目前主张晚期NSCLC应以非手术的综合治疗为主。近年来,以紫杉醇(pac litaxel,PTX)为代表的新一代抗肿瘤药物的临床试验被证实对NSCL At present, the incidence of lung cancer in China shows a rapid upward trend and has become the leading cause of death from cancer in cities. Non-small cell lung cancer (NSCLC) accounts for about 80% of lung cancer, and most patients have lost the chance of surgery at the time of their visit. Currently advocated that advanced non-surgical treatment of NSCLC based. In recent years, a new generation of antitumor drugs, such as paclitaxel (PTX), has been clinically proven for NSCL